Literature DB >> 34697665

Adverse Effects of Immunosuppression: Nephrotoxicity, Hypertension, and Metabolic Disease.

Jamael Hoosain1, Eman Hamad2.   

Abstract

The use of Immunosuppression has led to the tremendous improvement in graft survival. However, immunosuppressants have been found to cause a variety of metabolic derangements including but not limited to: insulin resistance and diabetes, hyperlipidemia, hypertension, and weight gain after transplantation. This combination of metabolic risk factors may be associated with increased cardiovascular disease (Grundy et al., Circulation 112(17):2735, 2005). In addition many transplant recipients may have many of these risk factors pre-transplant that are exacerbated by immunosuppression. These facts emphasize the need for rigorous follow-up and management of these risk factors post-transplant.The most common immune suppressant regimens may include different combinations of these agents: Corticosteroids, Calcineurin inhibitors (CNIs), Mammalian Target of Rapamycin (mTOR) Inhibitors, Antimetabolite.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Immunosupression; Metabolic disease; Nephrotoxicity

Mesh:

Substances:

Year:  2022        PMID: 34697665     DOI: 10.1007/164_2021_547

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  16 in total

1.  Unusual pattern of dyslipidemia in children receiving steroid minimization immunosuppression after renal transplantation.

Authors:  Keith K Lau; Daniel J Tancredi; Richard V Perez; Lavjay Butani
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

Review 2.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  Reversal of acute clinical and experimental organ rejection using large doses of intravenous prednisolone.

Authors:  P R Bell; J D Briggs; K C Calman; A M Paton; R F Wood; S G Macpherson; K Kyle
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

Review 4.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

5.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match.

Authors:  Kiran K Khush; Wida S Cherikh; Daniel C Chambers; Michael O Harhay; Don Hayes; Eileen Hsich; Bruno Meiser; Luciano Potena; Amanda Robinson; Joseph W Rossano; Aparna Sadavarte; Tajinder P Singh; Andreas Zuckermann; Josef Stehlik
Journal:  J Heart Lung Transplant       Date:  2019-08-10       Impact factor: 10.247

6.  Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Authors:  Vanessa P Houde; Sophie Brûlé; William T Festuccia; Pierre-Gilles Blanchard; Kerstin Bellmann; Yves Deshaies; André Marette
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

Review 7.  Optimizing the immunosuppressive regimen in heart transplantation.

Authors:  Howard Eisen; Heather Ross
Journal:  J Heart Lung Transplant       Date:  2004-05       Impact factor: 10.247

8.  A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension.

Authors:  Julie E Goodwin; Junhui Zhang; David S Geller
Journal:  J Am Soc Nephrol       Date:  2008-04-23       Impact factor: 10.121

Review 9.  Immunosuppression and transplant vascular disease: benefits and adverse effects.

Authors:  Farzad Moien-Afshari; Bruce M McManus; Ismail Laher
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

10.  Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience.

Authors:  J K Kirklin; R C Bourge; D C Naftel; W R Morrow; M H Deierhoi; R S Kauffman; C White-Williams; R I Nomberg; W L Holman; D C Smith
Journal:  J Heart Lung Transplant       Date:  1994 May-Jun       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.